Mdxhealth S.A. (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
$2.16
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.16
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$1.36 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)158.83K
Market Cap
$106.91M
Enterprise Value$177.03M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 14, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding49,497,334
10 Day Avg. Volume253,227
30 Day Avg. Volume158,832
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue1.64
Enterprise Value/Gross Profit2.75
Enterprise Value/Ebitda-28.59
Forecast
1Y Price Target
$6.54Price Target Upside202.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$138.30M
Bulls Say, Bears Say
Bulls Say
Acquisition-driven Commercial ExpansionIntegration of ExoDx expands the product menu and customer base, enabling the larger commercial team to accelerate conversion to liquid tests and drive meaningful revenue growth.
Clinical Evidence And Guideline AdoptionPositive data from the GPS‑ProMPT study and collaboration in the UK ProtecT trial could strengthen clinical evidence for the GPS test and increase guideline support and physician adoption, boosting test uptake.
Cost Discipline And Balance‑sheet ReliefDeferred earnout terms combined with operating expense discipline reduce cash and debt pressure and support margin improvement on the path toward sustainable positive free cash flow.
Bears Say
Acquisition-related Profit PressureHigher headcount and acquisition-related expenses associated with ExoDx lowered adjusted profitability measures and weighed on adjusted EBITDA.
Integration-related Revenue Timing RiskYear-end timing and integration issues tied to the ExoDx acquisition caused revenue to miss preliminary expectations, highlighting potential variability in near-term top‑line performance as systems are combined.
Product Reprioritization Leading To Sales ShortfallDeprioritizing select legacy products resulted in a sales shortfall versus expectations, signaling a risk that shifting the sales focus could temporarily depress revenue during the transition.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $1.36 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $106.91M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is May 14, 2026 which is in 40 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on Feb 26, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.15.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 49,497,334 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went down -4.225%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.54 (202.78% Upside)
$6.54 (202.78% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.00%
12-Months-Change
Fundamentals
Return on Equity
516.59%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Mdxhealth S.A.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company in growth and transition: strong top-line and unit growth (notably a 62% unit increase and 128% rise in liquid volumes), successful integration steps with ExoDx and a clearer path to cross-selling and clinical validation, offset by near-term profitability pressure from integration costs, higher operating and financial expenses, and a modest downward adjustment to reported revenue. Management provided optimistic 2026 guidance (approx. 28% revenue growth and a target of 10% adjusted EBITDA exiting the year) and secured earnout amendment relief (~$20M), signaling confidence in returning to operating leverage despite short-term headwinds.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$6.54
▲(202.78% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.26% Mutual Funds
44.29% Other Institutional Investors
54.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---